Search | Clinical Trials Finder

Conditions: Rheumatoid Arthritis
Interventions: Humax-CD4, Placebo; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 50
States / cities: Montgomery, Alabama • Long Beach, California • Rancho Cucamonga, California + 45 more

Conditions: Osteoarthritis, Traumatic Arthritis, Rheumatoid Arthritis, Congential Hip Dysplasia, Avascular Necrosis of the Femoral Head, Certain Cases of Ankylosis
Interventions: EMPHASYS Cup with VHN; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 21 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Gainesville, Florida • Gastonia, North Carolina

Conditions: Rheumatoid Arthritis
Interventions: abatacept; Biological
Lead sponsor: Arthritis & Rheumatic Disease Specialties Research; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Ankle Rheumatoid Arthritis, Arthritis of Ankle, Failure, Prosthesis
Interventions: Not listed
Lead sponsor: Exactech; Industry
Eligibility: 21 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2031
U.S. locations: 2
States / cities: Jacksonville, Florida • Durham, North Carolina

Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Interventions: AZD5492; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 4 more

Conditions: Sjogren's Syndrome
Interventions: Mini-Pill; Device
Lead sponsor: Tufts University; Other
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Arthrosis, Post Traumatic Arthritis, Rheumatoid Arthritis, Osteoarthritis
Interventions: Scandinavian Total Ankle Replacement System (STAR Ankle); Device
Lead sponsor: Encore Medical, L.P.; Industry
Eligibility: Not listed
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 6 more

Conditions: Primary Sjogren's Disease
Interventions: Telitacicept, Placebo; Biological · Drug
Lead sponsor: Vor Biopharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 43
States / cities: Chandler, Arizona • Flagstaff, Arizona • Glendale, Arizona + 37 more

Conditions: Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
Interventions: e-Device; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more

Conditions: Rheumatoid Arthritis
Interventions: tocilizumab [RoActemra/Actemra], Methotrexate, Simvastatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2008
U.S. locations: 10
States / cities: Anniston, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 7 more

Conditions: Rheumatoid Arthritis
Interventions: 50 mg LX3305 QD, 100 mg LX3305 QD, 150 mg LX3305 QD, 200 mg LX3305 QD, 250 mg LX3305 QD, 300 mg LX3305 QD, 400 mg LX3305 QD, 250 mg LX3305 BID, 500 mg LX3305 QD, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Andecaliximab, Placebo, Methotrexate, TNF Inhibitor; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: Palo Alto, California • DeBary, Florida • Las Vegas, Nevada + 5 more

Conditions: Arthritis, Rheumatoid
Interventions: placebo, ofatumumab; Other · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Anniston, Alabama • Miramar, Florida

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Not listed
Enrollment: 697 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis, Hypovitaminosis D
Interventions: Vitamin D, placebo; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 90 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis
Interventions: NKX019, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Nkarta, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 16
States / cities: Orange, California • Gainesville, Florida • Miami, Florida + 13 more

Conditions: Rheumatoid Arthritis
Interventions: GDC-0853, Adalimumab, Folic Acid, MTX, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Anniston, Alabama • Glendale, Arizona • Covina, California + 18 more

Conditions: Rheumatoid Arthritis
Interventions: BMS-986195, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: South Miami, Florida • Salt Lake City, Utah

Conditions: Sjogren's Syndrome
Interventions: Dazodalibep, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 37
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 34 more

Conditions: Rheumatoid Arthritis
Interventions: adalimumab, methotrexate, placebo; Biological · Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 1,032 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 49
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more

Conditions: Arthritis, Rheumatoid
Interventions: Golimumab Intravenous (IV), Infliximab, Biosimilar Infliximab; Biological
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 85
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 82 more

Conditions: Macrophage Activation Syndrome, Still's Disease, Adult-Onset, Stills Disease, Juvenile-Onset
Interventions: Chart review; Other
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 6 Months to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Atlanta, Georgia • Cincinnati, Ohio + 1 more

Conditions: Rheumatoid Arthritis
Interventions: secukinumab (AIN457), placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: Vestavia Hills, Alabama • Peoria, Arizona • Upland, California + 5 more

Search by objective public record fields.

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))

Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients

Exactech Vantage Total Ankle System Post Market Clinical Follow-Up - US Only

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

Sjogren's Mini-Pill Oral and Gut Microbiome Study

2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

Oral Health Assessment in Rheumatoid Arthritis and Other Autoimmune Diseases-- Anti- TNF Substudy

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients

Study of Arthritis and Related Conditions

Treatment of Hypovitaminosis D in Rheumatoid Arthritis

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis

Assessment of Macrophage Activation syndromE in STill's Disease

Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate